RESULTS	In the clinical study , ritonavir reduced triazolam clearance to < 4 % of control values ( p < .005 ) , prolonged elimination half-life ( 41 versus 3 hours ; p < .005 ) , and magnified benzodiazepine agonist effects such as sedation and performance impairment .\